Welcome to our dedicated page for Caredx SEC filings (Ticker: CDNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CareDx, Inc. filings document the formal record for a Nasdaq-listed precision medicine company focused on transplant testing, patient solutions, digital health technologies, and related diagnostic products. Recent Form 8-K filings furnish operating results, preliminary financial metrics, corporate presentations, and material agreements tied to the planned acquisition of Naveris and the sale of the Lab Products business to Eurobio Scientific.
The company’s regulatory disclosures also cover capital structure and governance matters, including common stock repurchase authorizations, inducement and equity incentive awards, executive officer changes, bylaw amendments, and shareholder derivative settlement materials. Its proxy statement details director elections, auditor ratification, advisory compensation votes, equity plan amendments, board governance, ownership information, and executive compensation.
On July 8, 2025, CareDx, Inc. (CDNA) director Michael Goldberg filed a Form 4 reporting receipt of 1,218 shares of common stock at a grant price of $0 under the company’s Outside Director Compensation Policy. The automatic equity award, issued in lieu of quarterly cash fees, raises his direct ownership to 154,216 shares. No open-market purchases, sales or derivative transactions were disclosed, indicating the filing is a routine governance matter rather than a signal of insider sentiment.
CareDx director Hannah Valantine has reported a significant insider transaction, selling 10,570 shares of common stock on June 18, 2025 at a weighted average price of $19.16 per share (ranging from $19.00 to $19.62). The total transaction value amounts to approximately $202,521.
The sale was executed under a Rule 10b5-1 trading plan established on December 12, 2024, which provides a pre-planned structure for insider trades. Following the transaction, Valantine retains direct ownership of 38,994 shares of CareDx common stock.
This transaction demonstrates a planned reduction in the director's holdings while maintaining a significant equity position in the company. The Rule 10b5-1 plan framework helps ensure compliance with insider trading regulations by establishing the trade parameters in advance.
CareDx Director Peter Maag has reported the sale of 10,000 shares of common stock at a weighted average price of $19.242 per share on June 17, 2025. The transaction was executed pursuant to a Rule 10b5-1 trading plan established on August 21, 2024.
The shares were sold in multiple transactions with prices ranging from $18.80 to $19.52. Following the reported transaction, Maag continues to hold 318,846 shares directly.
- Transaction Type: Sale (S)
- Ownership Type: Direct (D)
- Total Transaction Value: Approximately $192,420
- Trading Plan: Executed under pre-established 10b5-1 plan
This insider sale represents approximately 3% of Maag's direct holdings in CareDx and was conducted under a predetermined trading plan, which helps avoid concerns about insider trading.
CareDx, Inc. (CDNA) – Form 144 filing discloses a proposed sale of 10,570 common shares through Morgan Stanley Smith Barney on the NASDAQ. The shares, acquired as restricted stock units on 14 Jun 2025, carry an aggregate market value of $206,326.40, implying an indicative price of roughly $19.53 per share. The transaction is slated to occur on or about 18 Jun 2025. According to the filing, no other sales were made in the past three months, and the sale represents only ~0.02 % of the 55.68 million shares outstanding, suggesting minimal dilution or market impact. The filer certifies awareness of no undisclosed material adverse information and may be relying on a Rule 10b5-1 trading plan. Relationship to the issuer and filer identity were not provided in the excerpt.